Letter by Jiang et al Regarding Article, “Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial”

Key Points

• The letter addresses important findings from the PRADA II trial on sacubitril/valsartan in preventing cardiac issues during breast cancer treatment.
• Response to the clinical trial results discussed in the original article
• Focus on the implications of findings for future breast cancer therapies
• Encouragement for continued research and discussion
• Suggests reevaluation of cardiac protection strategies for breast cancer patients during therapy
• Calls for further studies to clarify long-term effects and benefits of sacubitril/valsartan